ACADIA Pharmaceuticals Inc. (ACAD) earnings
ACAD earnings moved a median of +0.85% by the close. Quarterly and annual ACAD reports and results, each read against the price at its own news timestamp. Back to the ACAD overview →
24 measured ACAD earnings events.
Where these ACAD earnings landedvs 24 measured ACAD earnings reactions
| Middle 50% of ACAD earnings reactions | -3.00% to +3.06% |
|---|---|
| Median reaction (to close) | +0.85% |
| Measured reactions | 24 |
Point-in-time · zero look-ahead
Half of the 24 ACAD earnings events with a measured close landed between -3.00% and +3.06%; 58% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q ACADIA PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +3.38% | +2.86% | |
| Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results | Press release | +3.38% | +2.86% | |
| Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 | Press release | -0.14% | -1.42% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | +1.46% | +3.06% | |
| Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance | Press release | +1.46% | +3.06% | |
| Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 | Press release | -0.62% | -2.79% | |
| Form 10-K ACADIA PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +2.23% | +5.62% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | -7.44% | -8.19% | |
| Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview | Press release | -7.44% | -8.19% | |
| Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 | Press release | +0.41% | -5.37% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +1.62% | +1.41% | |
| Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview | Press release | +1.62% | +1.41% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | +11.89% | +15.01% | |
| Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview | Press release | +11.89% | +15.01% | |
| Form 10-K ACADIA PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +0.68% | +2.94% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +4.53% | +9.62% | |
| Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview | Press release | +4.53% | +9.62% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +0.07% | -1.49% | |
| Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview | Press release | +0.07% | -1.49% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -6.69% | -13.09% | |
| Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview | Press release | -6.69% | -13.09% | |
| Form 10-K ACADIA PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +0.04% | -3.63% | |
| Form 10-Q ACADIA PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | -4.85% | +0.29% | |
| Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview | Press release | -4.85% | +0.29% |
Keep exploring
More ACAD: analyst actions → · SEC filings → · ACAD overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kazia Therapeutics Limited - American Depositary Shares (KZIA) | 393 | -1.07% | 34% |
| OHR PHARMACEUTICALS (OHRP) | 393 | 0.00% | 48% |
| BioXcel Therapeutics, Inc. (BTAI) | 392 | -0.75% | 41% |
| Karyopharm Therapeutics Inc. (KPTI) | 392 | -0.45% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.